BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Novo Nordisk A/S (NVO) Says New Data Show Victoza Advantage


11/27/2012 7:51:59 AM

Denmark's Novo Nordisk on Tuesday said new data showed an advantage for type two diabetes patients given its diabetes drug Victoza compared with rival drugs from Merck & Co and Amylin Pharmaceuticals Inc. The world's biggest insulin producer said in a statement that more type two diabetes patients given Victoza achieved an average blood sugar level below seven percent than those given Merck's sitagliptin (Januvia) or Amylin's exenatid BID. For non-diabetics, the usual blood sugar level is between 4 and five percent, while a level of 6.5 percent is considered good blood sugar control for people with diabetes.

Read at Reuters
Read at News Release
Read at Market Watch

   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->